Lactobacillus from yogurt could block drug-resistant infections

By Nathan Gray

- Last updated on GMT

Lactobacillus from yogurt could block drug-resistant infections
An isolate from a strain of Lactobacillus in commercial yogurt could block the growth of several multi drug-resistant bacteria, according to new data.

The strain, Lactobacillus parafarraginis​ KU495926, identified by 16S rRNA, was isolated from a sample of commercial yogurt – and showed typical characteristics, said those behind the research.

However, screening of the antimicrobial activity showed that an isolate from the strain – which is a unique bacteriocin-like peptide – blocked the growth of several multidrug-resistant / extended-spectrum beta-lactamase gram-negative bacterial pathogens.

Bacteriocins are antimicrobial peptides produced by bacteria and released to kill other related bacteria. The identified bacteriocin from Lactobacillus parafarraginis​ KU495926 is heat stable up to 121°C.

"Considering the current upsurge of antibiotic resistance in hospitals, especially among the gram-negative bacteria, and the exigent need to find viable alternatives, findings from the study may hold promise for possible therapeutic application,"​ said Rachelle Allen-McFarlane, doctoral candidate in the Biology Department at Howard University, Washington, D.C.

The study data was presented at ASM Microbe 2017 in New Orleans, Louisiana.

Related topics Research

Related news

Follow us

Products

View more

Webinars